Artificial intelligence (AI) and digital technologies are rapidly reshaping medical diagnostics and clinical trial execution. Pfizer-led initiatives employing AI algorithms are accelerating early detection of transthyretin cardiac amyloidosis (ATTR-CM) across global healthcare systems, enhancing diagnosis of this underrecognized cardiac condition. Additionally, momentum in obesity clinical trials has led sponsors to integrate digital tools like eCOAs and real-time analytics, coupled with patient-centered designs that account for complex comorbidity and behavior patterns. These methodological innovations enable more efficient trial conduct and better capture of patient experience. Furthermore, machine learning-powered platforms such as Fentanyl-Hunter are advancing forensic and toxicological detection of fentanyl metabolites, addressing opioid overdose crises. Collectively, these approaches illustrate AI’s growing utility in precision healthcare and streamlined drug development.